Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
A deep-seated Pseudomonas aeruginosa mouse kidney abscess model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of clinically relevant standard drugs. Following 50 mg/kg oral doses, twice daily for five consecutive days, clinafloxacin produced a 4 log decrease in mean bacterial count, the greatest decrease of all drugs tested. The same dosage regimen resulted in complete bacterial eradication in 88% of the kidneys. No other compound produced total bacterial clearance in 50% of the kidneys at the highest dose tested.
Shapiro
M A
MA
Department of Infectious Diseases, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
Sesnie
J C
JC
Desaty
T M
TM
Griffin
T J
TJ
Heifetz
C L
CL
D000038:Abscess / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D019540:Area Under Curve; D002442:Ceftazidime / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology; D015377:Cilastatin / Q000097:blood / Q000494:pharmacology; D000077728:Cilastatin, Imipenem Drug Combination; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004359:Drug Therapy, Combination / Q000097:blood / Q000494:pharmacology; D005260:Female; D024841:Fluoroquinolones; D006207:Half-Life; D015378:Imipenem / Q000097:blood / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000382:microbiology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D015363:Quinolones / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D004338:Drug Combinations; D024841:Fluoroquinolones; D015363:Quinolones; D015377:Cilastatin; D002939:Ciprofloxacin; D015378:Imipenem; C057477:clinafloxacin; D000077728:Cilastatin, Imipenem Drug Combination; D002442:Ceftazidime